THE TECFIDERA CHANNEL

Tecfidera (Dimethyl Fumarate)

Saturday, June 28, 2014

Tecfidera (Dimethyl Fumarate) and Tysabri (Natalizumab) Making Tons for Biogen Idec.
Posted by YDCtv at 10:27 AM
Email ThisBlogThis!Share to TwitterShare to FacebookShare to Pinterest
Labels: Tysabri
Newer Post Older Post Home

Blog Archive

  • ►  2016 (21)
    • ►  June (4)
    • ►  April (17)
  • ►  2015 (15)
    • ►  July (1)
    • ►  May (1)
    • ►  April (2)
    • ►  March (5)
    • ►  February (1)
    • ►  January (5)
  • ▼  2014 (187)
    • ▼  June (87)
      • Wow! It's no wonder MS is seen as a Cash Cow: THES...
      • Tecfidera and Ampyra Show Potential for Quality of...
      • GREAT TECFIDERA NEWS: One Year Post-Launch, All Su...
      • TECFIDERA RESEARCH REPORT
      • VIDEO: Multiple sclerosis death due to Tecfidera u...
      • MS Drug Tecfidera More Trouble Than It’s Worth?
      • Gastro Effects Dog Oral MS Drug Tecfidera: one-qua...
      • VIDEO: TEVA'S DISASTEROUS DROP IN STOCK PRICE:
      • Solid growth from Tecfidera (Dimethyl fumarate) in...
      • VIDEO: Dr. Timothy Vollmer
      • Data Show Declining Use of Injectables as Oral Mul...
      • Yvonne Decelis, Columnist: Today is day 5 on the "...
      • Yvonne Decelis, Columnist, MSnewsChannel.com
      • "Researchers don’t know why some multiple sclerosi...
      • NEUROLOGISTS NEED TO HAVE ...
      • Gastrointestinal Tolerability Study Of Tecfidera I...
      • Biogen beats revenue estimates as Tecfidera hits b...
      • Update
      • Neurologists Expect to Prescribe Biogen Idec’s Tec...
      • Researchers don’t know why some multiple sclerosis...
      • Biogen Idec to Present New Clinical Data from Its ...
      • Biogen Idec May Have Seeds For Next-Gen MS Drugs
      • Can new versions of Copaxone, Avonex drive market ...
      • Multiple Sclerosis Drug Tecfidera Becoming Increas...
      • AN IMPORTANT STUDY AVAILABLE TO EVERYONE ON TECFID...
      • Tecfidera – The Good, the Bad and the Ugly
      • HOW MS MEDICATIONS DIFFER FROM EACH OTHER
      • TECFIDERA: Biotech Stocks: Seeing Rainbows, Missin...
      • LEAD: Tecfidera is a new formulation of a drug tha...
      • biogens-winning-strategy? Biogen's share of that m...
      • Tecfidera Captures the Largest U.S. Neurologist-Re...
      • Biogen Idec: A Biotech Pioneer With A Stellar Futu...
      • Study to Evaluate Fatigue in Participants With Rel...
      • FDA panel supports approval of Sanofi's MS drug Le...
      • Tecfidera Is Off to a Quick Start
      • Study: Does the patient know best? Quality of life...
      • Yvonne Decelis, Columnist, MSnewsChannel.com
      • Merck KGaA shores up Rebif defenses to fend off ne...
      • Biogen Idec finished 2013 on a high note, with its...
      • HERE'S ANOTHER OF THE MANY ARTICLES THAT SAYS TECF...
      • Britain's regulatory agency turns down Biogen Idec...
      • Biogen Idec hits its first price hurdle for Tecfid...
      • FREE MS RESEARCH UPDATE: a comprehensive overview ...
      • Study: Effects of BG-12 (dimethyl fumarate) on hea...
      • "COPAXONE IS HEADED OFF A CLIFF: It's painfully cl...
      • STUDY: The changing fortunes of Tecfidera (dimethy...
      • Biogen Idec Inc: Tecfidera Continues Its Blisterin...
      • Biogen Said to Name Papadopoulos as Chairman, Repl...
      • Tecfidera (Dimethyl Fumarate) and Tysabri (Nataliz...
      • Tecfidera Qualifies as One of the Most Impressive ...
      • Biogen Idec said its fourth-quarter profit grew 57...
      • Biogen Idec Inc's high profile new multiple sclero...
      • Biogen Idec and UCB Enter Agreements to Commercial...
      • PLEASE GIVE RENE ((((HUGS))) FOR SHARING HER NEWS ...
      • Over the next five years, the global multiple scle...
      • Analyst Sees Rising Sales for Biogen Idec
      • Tecfidera EU launch not expected to do as well as ...
      • Royalty Pharma Acquires Additional Interest in TEC...
      • Biogen Leverages Strength In MS Treatments
      • Tecfidera Makes Top 3 FDA Approvals of 2013
      • Sanofi MS Drug Added With Genzyme Fails to Win FDA...
      • BioTrends Research Group Rolls Out The TreatmentTr...
      • Biogen Plant That Makes Older MS Drugs Fails An FD...
      • Tecfidera claimed the number two spot on the natio...
      • Biogen Idec and Samsung Bioepis to sell biosimilar...
      • Daniel Kantor, MD, on Specialty Pharmacy in Multip...
      • Surveyed Neurologists Report Significantly Higher ...
      • Multiple Sclerosis Cases Hit 2.3 Million Worldwide...
      • Terrible days ahead for Teva & Copaxone: Teva's pa...
      • 5 Blockbuster Drugs Going Off Patent in 2014
      • Biogen's Tecfidera Time-Out Pays Off
      • New drug for multiple sclerosis
      • 15 STUDIES IN SUNDAY'S NEWS
      • Alemtuzumab (marketed as Campath and currently und...
      • Treating Multiple Sclerosis in 2013DOCTORS DISCUSS...
      • 15 STUDIES IN SATURDAY'S NEWS
      • 15 STUDIES IN FRIDAY'S NEWS
      • 15 STUDIES IN THURSDAY'S NEWS
      • Biogen Jumps on Special Status for MS Drug in EU
      • 2/3 of Neurologists Have Prescribed Aubagio to The...
      • 15 STUDIES IN WEDNESDAY'S NEWS
      • 15 STUDIES IN TUESDAY'S NEWS
      • Tony Bodmer, Columnist, MSnewsChannel.com
      • KAYLA IS OUR MSer OF THE WEEK! (Neurologists: Kayl...
      • TECFIDERA WINS 10 YEARS OF PATENT PROTECTION: BIOG...
      • How Multiple Sclerosis Is Treated
      • Restructuring Can Help Teva's Copaxone Woes
    • ►  May (100)
  • ►  2013 (22)
    • ►  November (1)
    • ►  October (5)
    • ►  September (5)
    • ►  August (3)
    • ►  July (8)
Simple theme. Powered by Blogger.